WO1986000811A1 - Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same - Google Patents

Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same Download PDF

Info

Publication number
WO1986000811A1
WO1986000811A1 PCT/HU1985/000048 HU8500048W WO8600811A1 WO 1986000811 A1 WO1986000811 A1 WO 1986000811A1 HU 8500048 W HU8500048 W HU 8500048W WO 8600811 A1 WO8600811 A1 WO 8600811A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
diseases
preparations
treatment
avian
Prior art date
Application number
PCT/HU1985/000048
Other languages
French (fr)
Inventor
László CSATÁRY
Original Assignee
Csatary Laszlo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csatary Laszlo filed Critical Csatary Laszlo
Publication of WO1986000811A1 publication Critical patent/WO1986000811A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention relates to a set of therapeutic preparations (further on Preparation (s ) ) for the treatment of certain viral and other diseases , together with the complete technics of their production , including all materials and methods used.
  • the Preparations are effective against various pathological conditions caused by the Herpes group of viruses , and against certain malignant and benign tumours and collagen diseases as well.
  • Attenuated viral vaccines pre pared against some viral diseases of animals (Newcastle disease , Marek 's disease , avian bronchitis , avian encephalitis ) had a distinct therapeutic effect against various human diseases of known viral or unknown etiology.
  • the ob ject of the present invention is a set of preparations containing attenuated (or killed)
  • Newcastle disease virus Marek's disease virus , avian bronchitis virus or avian encephalitis virus , mixed in a carrier which is acceptable for use in humans.
  • the present invention relates also to all materials and methods used in the production of all preparations. The Preparations have already been used with very good result in the conditions listed below:
  • the Preparation containing attenuated Newcastle disease virus was active against the followin g conditions : a) Infections caused by viruses of the Herpes group , such as Herpex simplex I and II , Herpes zooster, Cytomegalovirus , infectious monon ⁇ cleoses (EpsteinBarr virus ) b) Aphthostomatitis c) Verruca vulgaris d) Infantile pharyngeal papilloma e) Human aden oca rein omas f ) Collagen diseases (e. g. nodous polyarteritis) g) Rheumatic arthritis
  • the Prepa ration containing attenuated avian bronchitis virus was active against the following conditions : a) Various human cancers b) Infections caused by the above listed (1.a) viruses of the Herpes goup.
  • the Preparations are produced by suspending live attenuated or inactivated , purified or highly purified and concentrated viruses in one of the carrier substances generally used in human pharmacology.
  • the Preparations may be supplemented with potentiating drugs (e.g. tranquilizers).
  • the optimal form of delivery of the Preparations is in a freeze-dried form , in sealed ampoules , with the diluent supplied in a separate vial.
  • the Preparations can be stored at room temperature for a practically unlimited time, toother forms of delivery are in solution , suppository , capsule , emulsion , suspension , ointment , etc. These should be stored in cold , for their activity may decay repidly at room temperature.
  • the dosage of the Preparations depends of their actual composition and form , on the patient 's general condition , and on stage (severity) of the disease actually treated.
  • the Preparations are non-toxic , and have no side effect whatever.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Therapeutic preparations against certain viral and other diseases of humans. The preparations are specified as formulas containing attenuated Newcastle disease virus, Marek's disease virus, avian bronchitis virus or avian encephalitis virus, mixed in carrier substance generally used in human pharmacology, if desired along with one or more optional potentiating preparations. Another object of the invention is the use of the above viruses in the treatment of virus diseases as well as malignant and benign tumours and collagen diseases.

Description

THE REPAUTIC PREPARATIONS FOR TREATMENT OF CERTAIN VIRAL AND OTTER DISEASES AND THE PREPARATION OF THE SAME
Technical field
The present invention relates to a set of therapeutic preparations (further on Preparation (s ) ) for the treatment of certain viral and other diseases , together with the complete technics of their production , including all materials and methods used. The Preparations are effective against various pathological conditions caused by the Herpes group of viruses , and against certain malignant and benign tumours and collagen diseases as well.
Background art
Inactivated or live attenuated viruses have long been used all over the world for the specific prevention of several viral diseases of humans and animals. We have found that certain attenuated viral vaccines , pre pared against some viral diseases of animals (Newcastle disease , Marek 's disease , avian bronchitis , avian encephalitis ) had a distinct therapeutic effect against various human diseases of known viral or unknown etiology.
Disclosure of invention
Accordingly the ob ject of the present invention is a set of preparations containing attenuated (or killed)
Newcastle disease virus , Marek's disease virus , avian bronchitis virus or avian encephalitis virus , mixed in a carrier which is acceptable for use in humans. The present invention relates also to all materials and methods used in the production of all preparations. The Preparations have already been used with very good result in the conditions listed below:
1. The Preparation containing attenuated Newcastle disease virus was active against the followin g conditions : a) Infections caused by viruses of the Herpes group , such as Herpex simplex I and II , Herpes zooster, Cytomegalovirus , infectious mononυcleoses (EpsteinBarr virus ) b) Aphthostomatitis c) Verruca vulgaris d) Infantile pharyngeal papilloma e) Human aden oca rein omas f ) Collagen diseases (e. g. nodous polyarteritis) g) Rheumatic arthritis
2. The Preparation containing attenuated Marek's disease virus acted against the following conditions : a ) Various human cancers (mainly a den oca rein omas ) b) Infections caused by viruses of the Herpes group as listed above (1.a)
3. The Prepa ration containing attenuated avian bronchitis virus was active against the following conditions : a) Various human cancers b) Infections caused by the above listed (1.a) viruses of the Herpes goup.
4. The Preparation containing attenuated avian encephalitis virus was active against the following conditions : a) Various human cancers
While most vaccines used for specific disease prevention in humans contain killed (inactivated) virus , all Preparations contain live attenuated virus. The possible mechanism of action of the Preparations is thus either an interference with the virulent viruses responsible for the actual disease , or a highly efficient aspecific stimulation of the natural protective mechanisms operative in the organism involved by disease.
The Preparations are produced by suspending live attenuated or inactivated , purified or highly purified and concentrated viruses in one of the carrier substances generally used in human pharmacology. The Preparations may be supplemented with potentiating drugs (e.g. tranquilizers).
The optimal form of delivery of the Preparations is in a freeze-dried form , in sealed ampoules , with the diluent supplied in a separate vial. In this form , the Preparations can be stored at room temperature for a practically unlimited time, toother forms of delivery are in solution , suppository , capsule , emulsion , suspension , ointment , etc. These should be stored in cold , for their activity may decay repidly at room temperature.
The dosage of the Preparations depends of their actual composition and form , on the patient 's general condition , and on stage (severity) of the disease actually treated. The Preparations are non-toxic , and have no side effect whatever.
The Preparations were tested in humans and animals , and showed a great therapeutic efficiency in both clinical and experimental trials.

Claims

Claims
1. Therapeutic preparation for the treatment of viral diseases and against malignant and benign tumours and collagen diseases characterized by containing live attenuated viruses selected from the group consisting of Newcastle disease virus , Marek's disease virus , avian bronchitis virus and avian encephalitis virus.
2. The preparation according to claim 1 characterized by containing at least one carrier.
3. Use of Newcastle disease virus , Marek's disease virus , avian bronchitis virus and avian encephalitis virus in the treatment of viral diseases , against malignant and benign tumours and collagen diseases.
4. The use of viruses according to claim 3 in the treatment of diseases caused by the Herpes group of viruses.
PCT/HU1985/000048 1984-07-30 1985-07-29 Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same WO1986000811A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU2919/84 1984-07-30
HU842919A HU197517B (en) 1984-07-30 1984-07-30 Process for production of terapeutical composition applicable against virus infection

Publications (1)

Publication Number Publication Date
WO1986000811A1 true WO1986000811A1 (en) 1986-02-13

Family

ID=10961677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU1985/000048 WO1986000811A1 (en) 1984-07-30 1985-07-29 Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same

Country Status (4)

Country Link
EP (1) EP0188590A1 (en)
AU (1) AU4638085A (en)
HU (1) HU197517B (en)
WO (1) WO1986000811A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260779A2 (en) * 1986-09-15 1988-03-23 Pitts, Ferris N., jr. Use of an immunostimulating medicament
EP0292293A2 (en) * 1987-05-19 1988-11-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Newcastle disease virus vaccine and method for the applicaton thereof
EP0312839A2 (en) * 1987-10-17 1989-04-26 Bayer Ag Method for the preparation of an inducer of non-specific immunity
EP0331102A1 (en) * 1988-03-01 1989-09-06 Volker Prof. Dr. Schirrmacher Virus-modified tumour vaccine for the immunotherapy of tumour metastases
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
US7056689B1 (en) 1993-04-30 2006-06-06 Wellstat Biologics Corporation Methods of treating and detecting cancer using viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US8043612B2 (en) 1997-10-09 2011-10-25 Wellstat Biologics Corporation Infection and treatment of neoplasms with vesicular stomatitis virus
US8105578B2 (en) 1997-10-09 2012-01-31 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US8377450B2 (en) 2009-11-30 2013-02-19 United Cancer Research Institute Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0713397T3 (en) * 1992-03-24 2003-03-31 United Cancer Res Inst Vaccine containing live virus

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1492083A1 (en) * 1962-02-01 1969-08-07 Philips Roxane Method for selecting a virus or other organism with the ability to induce protective resistance in an animal against a pathogen that is immunologically unrelated to the virus or organism
US3548054A (en) * 1969-06-06 1970-12-15 Lilly Co Eli Method for improving weight gains and reducing gross lesions in chickens exposed to marek's disease
DE2120929A1 (en) * 1970-04-29 1971-11-18 Merck & Co. Inc., Rahway, N.J. (V.StA.) Marek's chicken paralysis vaccine for poultry and process for its preparation
GB1274820A (en) * 1969-11-29 1972-05-17 Takeda Chemical Industries Ltd Highly attenuated newcastle disease virus vaccine and production thereof
US3674861A (en) * 1968-11-18 1972-07-04 Anthony Edward Churchill Live attenuated marek{40 s disease virus vaccine for poultry
US4049794A (en) * 1974-06-24 1977-09-20 Bayer Aktiengesellschaft Treatment of infections in animals
AT343797B (en) * 1974-08-01 1978-06-12 Stickl Helmut METHOD FOR PRODUCING A PREPARATION FOR TREATING INTERFERON-SENSITIVE INFECTIOUS DISEASES
AT346476B (en) * 1973-07-19 1978-11-10 Sevoian Martin METHOD FOR PRODUCING A VACCINE FOR IMMUNIZING POULTRY AGAINST MAREK'S DISEASE
FR2444467A1 (en) * 1978-12-20 1980-07-18 Gist Brocades Nv VACCINES FOR DISEASES CAUSED BY REOVIRUSES AND PROCESS FOR THE PREPARATION THEREOF
US4357320A (en) * 1980-11-24 1982-11-02 Gist-Brocades N. V. Infectious bronchitis vaccine for poultry
JPS58116422A (en) * 1981-12-28 1983-07-11 Green Cross Corp:The Antitumor agent
EP0086025A1 (en) * 1982-02-05 1983-08-17 Akzo N.V. Infectious bronchitis vaccines

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1492083A1 (en) * 1962-02-01 1969-08-07 Philips Roxane Method for selecting a virus or other organism with the ability to induce protective resistance in an animal against a pathogen that is immunologically unrelated to the virus or organism
US3674861A (en) * 1968-11-18 1972-07-04 Anthony Edward Churchill Live attenuated marek{40 s disease virus vaccine for poultry
US3548054A (en) * 1969-06-06 1970-12-15 Lilly Co Eli Method for improving weight gains and reducing gross lesions in chickens exposed to marek's disease
GB1274820A (en) * 1969-11-29 1972-05-17 Takeda Chemical Industries Ltd Highly attenuated newcastle disease virus vaccine and production thereof
DE2120929A1 (en) * 1970-04-29 1971-11-18 Merck & Co. Inc., Rahway, N.J. (V.StA.) Marek's chicken paralysis vaccine for poultry and process for its preparation
AT346476B (en) * 1973-07-19 1978-11-10 Sevoian Martin METHOD FOR PRODUCING A VACCINE FOR IMMUNIZING POULTRY AGAINST MAREK'S DISEASE
US4049794A (en) * 1974-06-24 1977-09-20 Bayer Aktiengesellschaft Treatment of infections in animals
AT343797B (en) * 1974-08-01 1978-06-12 Stickl Helmut METHOD FOR PRODUCING A PREPARATION FOR TREATING INTERFERON-SENSITIVE INFECTIOUS DISEASES
FR2444467A1 (en) * 1978-12-20 1980-07-18 Gist Brocades Nv VACCINES FOR DISEASES CAUSED BY REOVIRUSES AND PROCESS FOR THE PREPARATION THEREOF
US4357320A (en) * 1980-11-24 1982-11-02 Gist-Brocades N. V. Infectious bronchitis vaccine for poultry
JPS58116422A (en) * 1981-12-28 1983-07-11 Green Cross Corp:The Antitumor agent
EP0086025A1 (en) * 1982-02-05 1983-08-17 Akzo N.V. Infectious bronchitis vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Patent Abstracts of Japan, unexamined applications, section C, vol. 7, no. 219, issued 30 March 1983, The Patent Office Japanese Government, page 76 C 188, see Kokai-no. 58-116 422 (Midori Juji K.K.). *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260779A3 (en) * 1986-09-15 1989-06-07 Pitts, Ferris N., jr. Use of an immunostimulating medicament
EP0260779A2 (en) * 1986-09-15 1988-03-23 Pitts, Ferris N., jr. Use of an immunostimulating medicament
EP0292293A2 (en) * 1987-05-19 1988-11-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Newcastle disease virus vaccine and method for the applicaton thereof
US5152981A (en) * 1987-05-19 1992-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Newcastle disease virus vaccine and method for the application thereof
EP0292293A3 (en) * 1987-05-19 1990-01-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Newcastle disease virus vaccine and method for the applicaton thereof
US5094850A (en) * 1987-10-17 1992-03-10 Bayer Aktiengesellschaft Process for the preparation of inducers of non-specific immunity and product produced
EP0312839A2 (en) * 1987-10-17 1989-04-26 Bayer Ag Method for the preparation of an inducer of non-specific immunity
EP0312839A3 (en) * 1987-10-17 1990-03-14 Bayer Ag Method for the preparation of an inducer of non-specific immunity
EP0331102A1 (en) * 1988-03-01 1989-09-06 Volker Prof. Dr. Schirrmacher Virus-modified tumour vaccine for the immunotherapy of tumour metastases
WO1989007946A1 (en) * 1988-03-01 1989-09-08 Deutsches Krebsforschungszentrum Virally modified tumour vaccines for immunotherapy of tumour metastases
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
US7056689B1 (en) 1993-04-30 2006-06-06 Wellstat Biologics Corporation Methods of treating and detecting cancer using viruses
US7736640B2 (en) 1993-04-30 2010-06-15 Wellstat Biologics Corporation Methods of treating and detecting cancer using viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US8043612B2 (en) 1997-10-09 2011-10-25 Wellstat Biologics Corporation Infection and treatment of neoplasms with vesicular stomatitis virus
US8105578B2 (en) 1997-10-09 2012-01-31 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US8377450B2 (en) 2009-11-30 2013-02-19 United Cancer Research Institute Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Also Published As

Publication number Publication date
AU4638085A (en) 1986-02-25
EP0188590A1 (en) 1986-07-30
HUT40572A (en) 1987-01-28
HU197517B (en) 1989-04-28

Similar Documents

Publication Publication Date Title
Käufer et al. Significance of bursa of Fabricius as target organ in infectious bursal disease of chickens
Potkay Diseases of the Callitrichidae: a review
US4053582A (en) Attenuated fowl pox virus preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
Habel et al. Relationship of polyoma virus and tumor in vivo
Zawatzky et al. The Role of Interferon in the Resistance of CS7BL/6 Mice to Various Doses of Herpes Simplex Virus Type 1
Hilleman Prospects for the use of double-stranded ribonucleic acid (poly I: C) inducers in man
WO1986000811A1 (en) Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same
RU94002475A (en) Pharmaceutical composition and its use for viral infection treatment
Borden et al. The interferon refractory state: in vivo and in vitro studies of its mechanism
STRINGFELLOW et al. Interferon induction by 5-halo-6-phenyl pyrimidinones
Wagner Cellular resistance to viral infection, with particular reference to endogenous interferon
CA1095407A (en) Preparation for the treatment of herpes zoster and other herpes infections, as well as method for manufacture thereof
WO1986000529A1 (en) An antiviral preparation and the method of its production
Stringfellow et al. Interferon inducers in therapy of infection with encephalomyocarditis virus in mice. I. Effect of single doses of polyriboinosinic-polyribocytidylic acid and tilorone hydrochloride on viral pathogenesis
US4049794A (en) Treatment of infections in animals
US4039656A (en) Production of attenuated viruses
Melnick et al. Photodynamic inactivation of herpesvirus
JP2655726B2 (en) Newcastle disease virus live vaccine
Vizoso et al. Isolation of a virus resembling encephalomyocarditis from a red squirrel
JPS5970615A (en) Use of undecylenic acid for lip herpes therapy
Carroll et al. Resistance of visna virus to interferon
US4017359A (en) Production of non-antigenic attenuated viruses
US6080726A (en) Anti-viral and immuno stimulator polynucleotide duplex and use thereof
RU2005475C1 (en) Antiviral agent
UA42693C2 (en) The medicine for treating the infection by lentivirus, the preparation for human treatment which is infected by lentivirus.

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU BR DK FI JP MC NO RO SU US

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB IT LU NL SE